A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"

Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice

Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis

"Part A:~* Brain MRI at inclusion is allowed within 45 days before enrolment~* Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"

"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5."